CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » Brain Tumors

ONCOLOGY. Vol. 9 No. 1
 

Commentary (Laws): Current Management of Meningiomas

The De Monte Article Reviewed

By Edward R. Laws, Jr., MD1 | January 1, 1995
1University of Virginia Health Sciences Center, Charlottesville

Dr. DeMonte has used an interesting case report to provide an excellent summary of the state of the art in the management of meningiomas of the brain.

These lesions are the most common benign tumors affecting the central nervous system. For many years, they have represented a major challenge for neurosurgeons, both technically and conceptually [1]. The fact that most of these tumors can be cured surgically has stimulated a variety of innovative approaches. It has led to the recent developments of successful surgery within the cavernous sinus and successful approaches to the skull base--both areas that were previously considered surgically inaccessible.

(MORE: Current Management of Meningiomas)

There are many fascinating aspects to the problem of meningioma. The benign nature of most meningiomas makes them generally favorable lesions, ones which, at least theoretically, can be cured by surgical therapy alone. Sex and age predilection for the occurrence of meningiomas have been the foundation for investigation regarding the hormonal basis of tumor pathogenesis for this lesion. The presence of estrogen and progesterone(Drug information on progesterone) receptors on meningiomas has been well documented. As is pointed out in this review, this fact has served as the basis for attempts at hormonal therapy. These attempts are still under analysis.

Histologically, meningiomas can be differentiated into a number of different groups, but it is curious that the histology of the tumor rarely provides pertinent information with regard to the behavior of the lesion or its likelihood of recurrence. It appears that any histologic subtype of meningioma can have either a focal or a diffuse origin from the meninges, and there is no consistent correlation of specific type with intracranial location. What does appear to be correct, however, is that those tumors with a focal origin are the ones most likely to be cured surgically, and those with a more diffuse dural origin are those that tend to defy complete surgical resection and are most likely to recur following any form of treatment.

A Major Problem

The aggressive "cellular" or "atypical" meningioma represents a major problem in neurosurgical management. These tumors usually have suspicious histologic features, such as increased numbers of mitoses, but otherwise they look like fairly typical meningiomas. Unfortunately, they can follow a very aggressive course, with rapid and multiple recurrences unresponsive to standard forms of treatment. The nature of this aggressive change is not understood, and it represents a challenge for the future.

Equally difficult to explain has been the problem of cerebral edema surrounding many meningiomas [2]. A number of biochemical abnormalities have been identified, and a number of theories have been proposed in explanation of this phenomenon. It appears that the tumor "poisons" the surrounding brain, producing the edematous reaction, but the nature of this process is still speculative. Fortunately, this edema usually responds well to treatment with steroids, which sometimes need to be maintained for relatively long periods following successful surgery.

The peculiar features of meningioma biology surely are clues to the basic nature of this tumor and its etiology. Current studies emphasizing the molecular biology of these lesions offer great promise in helping us deal more effectively with meningiomas in the future. With the accurate characterization of tumor cell receptors, particularly with hormone receptors, new avenues for diagnosis and therapy are developing. With information regarding alterations in the genome of meningiomas [3], the opportunity for novel forms of diagnosis and therapy exist, and should hold significant promise as our basic understanding of this difficult tumor evolves.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

This commentary refers to the following article

Current Management of Meningiomas



Franco De Monte, MD, FRCS(C)


1. Newman SA: Meningiomas: A quest for the optimum therapy. J Neurosurg 80:191-194, 1994.

2. Philippon J, Foncin JF, Grob R, et al: Cerebral edema associated with meningiomas: Possible role of a secretory-excretory phenomenon. Neurosurgery 14:295-301, 1989.

3. Detta A, Kenny BG, Smith C, et al: Correlation of proto-oncogene expression and proliferation in meningiomas. Neurosurgery 33:1065- 1074, 1993.


CancerNetwork on Facebook


 
RELATED CONTENT

Molecular Classification of Diffuse Gliomas
ONCOLOGY,  June 18, 2013
Tailored Therapy in Diffuse Gliomas: Using Molecular Classifiers to Optimize Clinical Management
ONCOLOGY,  June 18, 2013
ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma
June 10, 2013
Oligodendrogliomas: Questions Answered, Answers Questioned
ONCOLOGY,  April 15, 2013
Treatment of Anaplastic Oligodendrogliomas: Should Resources Be Used to Codify the Old or to Create the New?
ONCOLOGY,  April 15, 2013
 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • Radiation-Induced Enteritis: Incidence, Mechanisms, and Management
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
Click here to subscribe to our newsletter



 
SearchMedica Search Result

Find peer-reviewed literature and websites for practicing medical professionals

CME on Brain Tumors
Evidence on Brain Tumors
Guidelines on Brain Tumors
Patient Education on Brain Tumors
Clinical Trials on Brain Tumors
Practical Articles on Brain Tumors
Research and Reviews on Brain Tumors
All "Brain Tumors" results

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy